Setting

North America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

Published: 30 Mar 2021 | Report Code: 10247951 | Pages: 125

North America pharmaceutical manufacturing industry is expected to grow by 11.0% annually in the forecast period and reach $241.76 billion by 2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic. Highlighted with 26 tables and 60 figures, this 125-page report “North America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Industry Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Industry Opportunities • Porter’s Fiver Forces The trend and outlook of North America industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country. Based on Formulation, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Tablets • Capsules • Injectable • Sprays • Suspensions • Powders • Other Formulations Based on Route of Administration, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Oral Medicine • Topical Medicine • Parenteral Medicine • Inhalations • Other Routes of Administration Based on Age Group, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Children & Adolescents • Adults • Geriatric Based on Therapeutic Application, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Cardiovascular Diseases • Pain • Diabetes • Cancer • Respiratory Diseases • Neurological Diseases • Orthopedics • Other Applications Based on Drug Type, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Based on Distribution Channels, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Retail Channels • Non-retail Channels Based on Manufacturing Facility, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • In-house Facility • Outsourced Facility Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Aenova Group Amgen AstraZeneca Catalent Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences GlaxoSmithKline plc Johnson & Johnson Lonza Group Lupin Merck & Co., Inc. Novartis AG Novo Nordisk Pfizer, Inc. Roche Sanofi SA Takeda (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) 

Table Of Contents

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Industry Research Methodology 11
1.2.2 Industry Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Industry Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Industry Overview and Dynamics 20
2.1 Industry Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Industry 24
2.2 Major Growth Drivers 26
2.3 Industry Restraints and Challenges 29
2.4 Emerging Opportunities and Industry Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of North America Industry by Formulation 40
3.1 Industry Overview by Formulation 40
3.2 Tablets 42
3.3 Capsules 43
3.4 Injectable 44
3.5 Sprays 45
3.6 Suspensions 46
3.7 Powders 47
3.8 Other Formulations 48
4 Segmentation of North America Industry by Route of Administration 49
4.1 Industry Overview by Route of Administration 49
4.2 Oral Medicine 51
4.3 Topical Medicine 52
4.4 Parenteral Medicine 53
4.5 Inhalations 54
4.6 Other Routes of Administration 55
5 Segmentation of North America Industry by Age Group 56
5.1 Industry Overview by Age Group 56
5.2 Children & Adolescents 58
5.3 Adults 59
5.4 Geriatric 60
6 Segmentation of North America Industry by Therapeutic Application 61
6.1 Industry Overview by Therapeutic Application 61
6.2 Cardiovascular Diseases 63
6.3 Pain 64
6.4 Diabetes 65
6.5 Cancer 66
6.6 Respiratory Diseases 67
6.7 Neurological Diseases 68
6.8 Orthopedics 69
6.9 Other Applications 70
7 Segmentation of North America Industry by Drug Type 71
7.1 Industry Overview by Drug Type 71
7.2 Branded Prescription Drugs 73
7.3 Generic Prescription Drugs 74
7.4 OTC Drugs 75
8 Segmentation of North America Industry by Distribution Channels 76
8.1 Industry Overview by Distribution Channels 76
8.2 Retail Channels 78
8.3 Non-retail Channels 79
9 Segmentation of North America Industry by Manufacturing Facility 80
9.1 Industry Overview by Manufacturing Facility 80
9.2 In-house Facility 82
9.3 Outsourced Facility 83
10 North America Industry 2020-2027 by Country 84
10.1 Overview of North America Industry 84
10.2 U.S. 87
10.3 Canada 91
10.4 Mexico 93
11 Competitive Landscape 95
11.1 Overview of Key Vendors 95
11.2 New Product Launch, Partnership, Investment, and M&A 98
11.3 Company Profiles 99
Abbott Laboratories 99
Aenova Group 101
Amgen 102
AstraZeneca 103
Catalent Inc. 104
Eli Lilly and Company 105
F. Hoffmann-La Roche Ltd. 106
Gilead Sciences 107
GlaxoSmithKline plc 108
Johnson & Johnson 109
Lonza Group 110
Lupin 111
Merck & Co., Inc. 112
Novartis AG 113
Novo Nordisk 114
Pfizer, Inc. 115
Roche 116
Sanofi SA 117
Takeda 118
12 Investing in North America Industry: Risk Assessment and Management 119
12.1 Risk Evaluation of North America Industry 119
12.2 Critical Success Factors (CSFs) 122
Related Reports and Products 125

List Of Tables

Table 1.  Snapshot of North America Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027 18
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3.  Main Product Trends and Industry Opportunities in North America Pharmaceutical Manufacturing Industry 32
Table 4. North America Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 40
Table 5. North America Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 49
Table 6. North America Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn 56
Table 7. North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn 61
Table 8. North America Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 71
Table 9. North America Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn 76
Table 10. North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn 80
Table 11. North America Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 85
Table 12. U.S. Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 89
Table 13. U.S. Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 89
Table 14. U.S. Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 89
Table 15. Canada Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 92
Table 16. Canada Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 92
Table 17. Canada Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 92
Table 18. Mexico Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 94
Table 19. Mexico Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 94
Table 20. Mexico Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 94
Table 21. Abbott Laboratories: Company Snapshot 99
Table 22. Abbott Laboratories: Business Segmentation 99
Table 23. Abbott Laboratories: Product Portfolio 100
Table 24. Abbott Laboratories: Revenue, 2017-2019, $ bn 100
Table 25.  Risk Evaluation for Investing in North America Industry, 2020-2027 120
Table 26. Critical Success Factors and Key Takeaways 123


List Of Figures

Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation 15
Figure 4. North America Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17
Figure 5. North America Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Manufacturing Industry 26
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical Manufacturing Industry 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical Manufacturing Industry 36
Figure 11. Breakdown of North America Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue 41
Figure 12. Contribution to North America 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%) 41
Figure 13. North America Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn 42
Figure 14. North America Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn 43
Figure 15. North America Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn 44
Figure 16. North America Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn 45
Figure 17. North America Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn 46
Figure 18. North America Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn 47
Figure 19. North America Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn 48
Figure 20. Breakdown of North America Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue 50
Figure 21. Contribution to North America 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%) 50
Figure 22. North America Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn 51
Figure 23. North America Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn 52
Figure 24. North America Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn 53
Figure 25. North America Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn 54
Figure 26. North America Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn 55
Figure 27. Breakdown of North America Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue 56
Figure 28. Contribution to North America 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%) 57
Figure 29. North America Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn 58
Figure 30. North America Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn 59
Figure 31. North America Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn 60
Figure 32. Breakdown of North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue 62
Figure 33. Contribution to North America 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 62
Figure 34. North America Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn 63
Figure 35. North America Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn 64
Figure 36. North America Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn 65
Figure 37. North America Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn 66
Figure 38. North America Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn 67
Figure 39. North America Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn 68
Figure 40. North America Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn 69
Figure 41. North America Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn 70
Figure 42. Breakdown of North America Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue 71
Figure 43. Contribution to North America 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 72
Figure 44. North America Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn 73
Figure 45. North America Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn 74
Figure 46. North America Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn 75
Figure 47. Breakdown of North America Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue 76
Figure 48. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%) 77
Figure 49. North America Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn 78
Figure 50. North America Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn 79
Figure 51. Breakdown of North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue 81
Figure 52. Contribution to North America 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%) 81
Figure 53. North America Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn 82
Figure 54. North America Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn 83
Figure 55. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 85
Figure 56. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 86
Figure 57. U.S. Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 88
Figure 58. Canada Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 91
Figure 59.  Pharmaceutical Manufacturing Industry in Mexico, 2017-2027, $ bn 93
Figure 60. Growth Stage of North America Industrial Robot Software Industry over the Forecast Period 95

Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda